



# **RETHINKING WHAT'S POSSIBLE WITH VACCINES**

**Bell Potter Healthcare Conference**

November 16, 2023



# Forward Looking Statements

This presentation/material regarding Vaxxas Pty. Ltd., together with its subsidiaries (the “**Company**”), is only for the information of the intended recipient and may not be used, published or redistributed without the prior written consent of the Company. This presentation also contains forward-looking statements. In some cases, you can identify forward-looking statements by the words “will,” “expect,” “intend,” “plan,” “objective,” “believe,” “estimate,” “potential,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. These statements are based on Company management’s current beliefs and expectations, and include, but not exclusively, statements regarding the Company’s financial results, future financial position, expected growth, business strategy, budgets, projected costs, projected capital expenditures, plans, objectives, regulatory approvals, industry trends, market size and growth opportunities. Certain of the economic, statistical and financial market information contained herein was obtained from published sources prepared by other parties. While such sources are believed to be reliable for the purpose used in the Company, none of the Company or any of its affiliates and none of the directors, officers, partners, employees, agents, shareholders, associates or affiliates of any of them assume any responsibility for the accuracy of the information, and none has independently verified any of the information contained herein.

# WE ARE DEVELOPING THE FUTURE OF VACCINATION



## Vaxxas HD-MAP High Density Microarray Patch


- 1 Easier to administer...
- 2 Easier to manage...
- 3 More immunogenic...
- 4 Requires less antigen...
- 5 ...at same/lower cost






# THE PROBLEM: NEEDLE AND SYRINGE

## 170 Year-old Technology



## Untargeted Science



**Slow onset of immune response**

## CHALLENGES



### Patient Dissatisfaction

- Painful injection
- Slow immune response



### Lower Profitability

- High dosing
- High COGS/system costs



### Inefficient Distribution/Protection

- Cold chain storage/distribution
- Skilled administration required

# THE SOLUTION: VAXXAS HD-MAP



## BENEFITS



Patients

### Patient Preference

- No fear of needle pain
- Faster immune response



Pharma

### Higher Profitability

- Demonstrated (6x) dose sparing
- Lower COGS, more revenue



Global Health

### Improved Distribution/Protection

- Thermostable with easy distribution
- Easy to administer/self-admin potential


# SUPERIOR IMMUNE RESPONSE AND LOWER DOSING POTENTIAL



Results from a Randomized Controlled Phase I Influenza Vaccine Clinical Trial in 210 Subjects <sup>†</sup>

## Superior Immune Response


*Patch induces higher titre than injection*



\*\*  $p < 0.01$  v injection  
\*  $p < 0.05$  v injection

## Lower Dose of Vaccine Required

*1/6<sup>th</sup> dose by patch equivalent to full dose by syringe*



12 Month Stability 40C

<sup>†</sup> Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled Phase I clinical trial: A.H. Forster et al (2020) <http://doi.org/10.1371/journal.pmed.1003-24>



# VAXXAS SNAPSHOT







- Founded 2011
- \$100M venture funding, \$140M non-dilutive funding
- Team 140 strong (136 Australia & 4 USA)
- Partnered with global leaders in vaccination
- Completed 3 Phase I vaccine studies >300 participants
- 2 Phase I studies, 200 participants wrapping up
- 8 development programs advancing
- Establishing high-volume, low-cost manufacturing at new Vaxxas Biomanufacturing Facility






# HD-MAP IS A PLATFORM FOR VACCINATION

Demonstrated Preclinically Across All Major Vaccine Formats

Type of vaccine		Vaccines	Preclinical delivery demonstrated using Vaxxas' HD-MAP technology
<b>Live attenuated virus</b>		Measles, mumps, rubella, yellow fever, influenza, typhoid, BCG Japanese encephalitis, rotavirus	<ul style="list-style-type: none"> <li>• Seasonal influenza</li> <li>• Pandemic influenza</li> <li>• Measles rubella</li> </ul>
<b>Killed whole organism</b>		Whole-cell pertussis, polio, influenza, Japanese encephalitis, hepatitis A, rabies	<ul style="list-style-type: none"> <li>• Poliovirus</li> <li>• Chikungunya virus</li> </ul>
<b>Protein subunit</b>		Pertussis, influenza, hepatitis B, meningococcal, pneumococcal, hepatitis A	<ul style="list-style-type: none"> <li>• Dengue</li> <li>• SARS-CoV-2</li> </ul>
<b>Virus-like particle</b>		Human papillomavirus	<ul style="list-style-type: none"> <li>• Human papillomavirus</li> </ul>
<b>Polysaccharide conjugate</b>		<i>Haemophilus influenzae</i> type B, pneumococcal, meningococcal, typhoid	<ul style="list-style-type: none"> <li>• Pneumococcus</li> <li>• Group A streptococcus</li> </ul>
<b>Nucleic acid vaccine</b>		SARS-COV-2	<ul style="list-style-type: none"> <li>• West Nile virus</li> <li>• Herpes simplex virus</li> <li>• siRNA</li> </ul>

# FOCUSED ON FOUR MAJOR COMMERCIAL SEGMENTS



## VAXXAS PRODUCT PORTFOLIO

In-licensing best-in-class vaccine assets

COVID-19



## PANDEMIC/ BIODEFENSE

Modernizing preparedness



## PHARMA PARTNERING

Differentiation, increasing reach and profitability



Undisclosed


## GLOBAL HEALTH

Revolutionary impact for those most in need



BILL & MELINDA GATES foundation

# EIGHT PROGRAMS UNDERWAY WITH LEADING PARTNERS









# THE WORLD'S FIRST VACCINE PATCH

**Vaxxas Biomedical Facility  
Northshore Brisbane, Australia**






# Vaxxas Biomedical Facility

## R&D + Pilot Manufacturing

- 5,500 m<sup>2</sup> / 60,000 ft<sup>2</sup>
- Labs, cleanrooms, warehouse, offices
- TGA manufacturing license program underway for late-stage clinical (II/III)
- Clinical + first commercial products
- Designed for end-to-end pilot manufacturing (device components & assembly, aseptic coating/finishing)
- When fully operational, capacity to manufacture tens-of-millions of vaccine HD-MAPs/year


VBF is a blueprint for tech transfer of equipment & processes to replicate for manufacturing facilities globally





# GROWTH: TECHNOLOGY→VALUE→PARTNERSHIPS (REPEAT)

## ~A\$100M Venture + ~A\$140M Non-Dilutive Funding



Vaccine + Vaccination = Protection

